A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015

Kaaij, Rosa T. van der; Koemans, Willem J.; Putten, Margreet van; Snæbjörnsson, Pétur; Luijten, Josianne; Dieren, Jolanda M. van; Cats, Annemieke; Lemmens, Valery; Verhoeven, Rob H.A.; Sandick, Johanna W. van

doi:10.1016/j.ejca.2020.02.017

Cited by 51 publications

(31 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Highly differentiated and intestinal types are good behaviors directing betted prognosis in most GC patients, which might indicate that the intensity of treatment could be reduced [35][36][37]. However, the results of the current study were just the opposite in pT1N1M0 GC patients.…”

Section: Discussioncontrasting

confidence: 64%

Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: Should radiotherapy be added to chemotherapy? A propensity score-matched analysis

et al. 2021

View full text Add to dashboard Cite

Background: Early gastric cancer (EGC) with metastatic lymph nodes (mLNs) has a relatively higher recurrence rate and poorer prognosis than EGC without mLNs. However, the postoperative treatment directions of pT1N1M0 vary from different guidelines. This study attempted to confirm the value of postoperative treatments in pT1N1M0 GC patients. Methods: Overall, 379 patients with pT1N1M0 GC following gastrectomy from 2000 to 2016 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score-matched (PSM) analysis was used to reduce bias. Overall survival was analyzed by Kaplan-Meier method and the log-rank test. Cox proportional hazards regression analyses were used to confirm the independent prognostic factors. Results: Before matching, the results of survival analyses indicated that adjuvant chemotherapy (ACT) and chemoradiotherapy (ACRT) could significantly prolong the survival time of the cohort (P < 0.05). After PSM analysis, 136 patients remained and ACRT maintained significance in the survival analysis (P = 0.018). Furthermore, patients with well or moderately differentiated GC (HR = 0.226, P =0.018) or intestinal type GC (HR = 0.380, P = 0.040) achieved a significantly superior prognosis with ACRT, compared to patients receiving ACT. Conclusion: The survival benefit of ACRT and ACT for pT1N1M0 GC patients following gastrectomy was confirmed in the SEER cohort. RT added to ACT might be recommended according to Lauren's classification and tumor grade in clinical decision making.

show abstract

Section: Discussioncontrasting

confidence: 64%

Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: Should radiotherapy be added to chemotherapy? A propensity score-matched analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Классификация ВОЗ для опухолей ЖКТ, изданная в 2019 году, выделяет 5 основных гистологических типов РЖ: тубулярный, папиллярный, муци-нозный, карцинома из плохо сцепленных клеток (включая перстневидноклеточный вариант) и смешанный, а также редкие гистологические подтипы [12]. Мы обратили внимание, что в большинстве публикаций классификация ВОЗ считается альтернативной, а основное внимание уделяется классификации Lauren [13][14][15][16][17]. Несмотря на различия в терминологии основные подтипы схожи по клинико-морфологическим признакам.…”

Section: актуальностьunclassified

Using the digital archive of pathological reports of stomach cancer as internal quality control of coding according to the ICD-O system

Fomenko

Karnaukhov

Лаптева

et al. 2021

jour

View full text Add to dashboard Cite

Purpose of the study. Demonstrate the possibilities of statistical analysis of the digital archive at pathological department (PD). To conduct internal quality control of the coding of malignant tumors according to the ICD-O-3 system of pathology reports using the example of gastric cancer (GC).Materials and methods. We retrospectively analyzed the digital archive of 368,157 pathology reports of the National Medical Research Centre for Oncology of the Ministry of Health of Russia from 2000 to 2019. For the study, 4,857 pathology reports of patients operated for gastric malignancies (ICD-X codes: C16.0 – C16.9) were selected for the period from 2000 to 2019.Results. The analysis of 368,157 protocols of the digital archive of PD revealed 4,614 malignant epithelial tumors of the stomach: tubular adenocarcinoma – 2,958, signet ring cell carcinoma – 791, undifferentiated cancer – 565, mucinous adenocarcinoma – 210, neuroendocrine neoplasia – 90. A significant increase in the ICD-O codes for "adenocarcinoma NOS" was found in 2018 and 2019. The pathology reports for these 2 years were reviewed by an independent pathologist and changes were made to the ICD-O codes according to the WHO classification digestive system tumors 2019. The adenocarcinoma NOS (8140/3) was replaced by the codes: tubular adenocarcinoma (ICD-O: 8211/3) – 41%, papillary adenocarcinoma (8260/3) – 9% and adenocarcinoma with mixed subtypes (8255/3) – 29%.Conclusion. The study, based on analysis of coding ICD-O stomach MN demonstrated the importance of digital archive at the PD, as a tool for rapid static analysis pathology reports and quality control of coding. The coding system can be the basis for large multicenter studies in oncology. Therefore, it is important to control the quality of coding of the pathology reports and to timely update the codes when new pathological classifications are released.

show abstract

“…A side-study from the FLOT4-AIO study has been performed, which also showed that intestinal type gastric cancer achieved more frequently a pathologic complete response (23%) compared to diffuse type (10%) on preoperative treatment with FLOT (43). In addition, patients with diffuse type gastric cancer have a poorer OS compared to patients with intestinal type (69)(70)(71).…”

Section: Lauren Classificationmentioning

confidence: 99%

Towards Personalization in the Curative Treatment of Gastric Cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Gastric cancer is the fifth most common cancer worldwide and has a high mortality rate. In the last decades, treatment strategy has shifted from an exclusive surgical approach to a multidisciplinary strategy. Treatment options for patients with resectable gastric cancer as recommended by different worldwide guidelines, include perioperative chemotherapy, pre- or postoperative chemoradiotherapy and postoperative chemotherapy. Although gastric cancer is a heterogeneous disease with respect to patient-, tumor-, and molecular characteristics, the current standard of care is still according to a one-size-fits-all approach. In this review, we discuss the background of the different treatment strategies in resectable gastric cancer including the current standard, the specific role of radiotherapy, and describe the current areas of research and potential strategies for personalization of therapy.

show abstract

A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015

Cited by 51 publications

References 30 publications

Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: Should radiotherapy be added to chemotherapy? A propensity score-matched analysis

Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: Should radiotherapy be added to chemotherapy? A propensity score-matched analysis

Using the digital archive of pathological reports of stomach cancer as internal quality control of coding according to the ICD-O system

Towards Personalization in the Curative Treatment of Gastric Cancer

Contact Info

Product

Resources

About